Palbociclib companion biomarker unraveled
Researchers at the Universities of Dundee and Newcastle have identified a previously unknown target for the breast cancer drug palbociclib, which can be used to identify treatment responders.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2128 entries already.
Entries by Thomas Gabrielczyk
GMP and new processes: be prepared for hassle
Poor aseptic practices can rapidly ruin market supply of products outsourced for production. This year, Celltrion came under fire from FDA inspectors. At the end of January, the producer received a warning letter affecting the production of Inflectra biosimilar infliximab-dyyb (CT- P13) co-marketed with Pfizer. In mid-February, the FDA added a warning concerning rituximab and trastuzumab biosimilars produced for Teva, as well as for its fast-track migraine mAb fremanezumab.
GBS 2018: Bioeconomy leaders foster shift to sustainable industry production
International collaboration is needed to secure living of the growing world population without collapse of the planet’s resources, biodiversity and climate. A communique published at the end of the Global Bioeconomy Summit (GBS) outlines policy measures needed to create a biobased economy for all.
A bioengineered tattoo monitors blood calcium levels
Swiss researchers have created a biomedical tattoo that becomes visible on the skin of mice in response to elevated levels of calcium in the blood.
German biotech sector growing
The German biotech industry has shown tremendous growth in 2017. According to figures of BIOCOM, turnover, employees or number of start-ups – many key figures for 2017 exceeded those of the record year 2016.
Servier to bag Shire’s cancer business
French Servier boosts its cancer drug portfolio acquiring Shire plc’s oncology pipeline, which earned about US$260m last year, for US$2.4bn in cash.
Germany to boost the bioeconomy
Shortly before the Global Bioeconomy Summit (19.-20.4.2018) in Berlin will begin, Germany’s new Research Minister Anja Karliczek announced three major initiatives to strengthen the biologisation of the industry and the foundation of innovative biotechs.
Canopy acquires Czech Annabis Medical sro
Canopy Growth Corp. is growing its medical cannabis business in Europe with the acquisition of Czech market leader Annabis Medical sro.
GSK pass orphan gene therapy assets to Orchard Therapeutics
British drug major GlaxoSmithKline (GSK) has passed its orphan autologous cell and gene therapy pipeline including its EU-approved ADA-SCID treatment Strimvelis to British/US Orchard Therapeutics. GSK acquired a 19,9% equity stake in Orchard and a board membership.
Alexion in €639m bid for Wilson Therapeutics AB
A public offer from orphan drug major Alexion Pharmaceuticals Inc. has been accepted by Wilson Therapeutics‘ Board of Directors. Alexion’s SEK232/share bid would total in an acqusition price of SEK6.564bn or €638.8m.